The simpleton's error in drug development [2]

Journal of Clinical Oncology

Volumn 20, Issue 23, 2002, Pages 4606-4607

  Castro, Michael ^a  

^a Charles Wood Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IMATINIB; TRASTUZUMAB;

CANCER CHEMOTHERAPY; DRUG APPROVAL; DRUG EFFICACY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; DRUG DESIGN; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0036896488     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.99.183     Document Type: Letter

References (5)

1. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499, 2002
2. Lung Cancer Trial Results Show No Improvement for the Combined Treatment of Iressa (ZD1839) with Standard Platinum-Based Therapy. Wilmington, DE, AstraZeneca Pharmaceutical Co, August 19, 2002 (press release)
3. Fukuoka M, Yano S, Giaccone G, et al: Final results from a phase II trial of ZD1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc Am Soc Clin Oncol 21:298a, 2002 (abstr 1188)
4. Kris MG, Natale RB, Herbst RS, et al: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1166)
5. Ruckdeschel JC, Simon G, Antonia S, et al: ZD1839 ('Iressa') as a single agent for the treatment of metastatic non-small-cell lung cancer. Proc Am Soc Clin Oncol 21:318a, 2002 (abstr 1269)